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Announcements Fellowships, Grants, & Awards
Pilot and Feasibility Clinical Research Grants in
Kidney or Urologic Diseases (R21)
The Division of Kidney, Urologic, and Hematologic
Diseases of the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) has a long-
standing and substantial interest in research concern-
ing the prevention and treatment of kidney or urologic
disorders. This program announcement is a reissuance
of PAR-04-065, and speciﬁcally encourages the sub-
mission of applications for pilot and feasibility clinical
and translational research studies, including clinical tri-
als, and epidemiologic studies, related to kidney or
urologic disease research that address important clini-
cal and translational questions and are potentially of
high impact. It is anticipated that applications for pilot
and feasibility studies may lead to full-scale clinical
studies, including diagnostic strategies, epidemiologic
studies, or trials in the diagnosis, prevention, preemp-
tion, or treatment of kidney or urologic disease.
These grants may be used for plan, pilot, or imple-
ment trials that evaluate pharmacologic, dietary, surgi-
cal, or behavioral interventions for the prevention or
treatment of kidney or urologic disease. Pilot epidemio-
logic studies are also encouraged. It is anticipated that
these grants will in some cases serve as a basis of plan-
ning future multicenter research project grant applica-
tions (R01), or for cooperative agreement (U01)
applications. The purpose of the planning grant is to
provide support for investigators at different institu-
tions to meet and design common protocols, entry cri-
teria, data management systems, analysis plans and
pilot data for a clinical trial. This would allow investiga-
tors to obtain additional expertise during the trial plan-
ning phase in areas such as clinical trial design and
statistics to develop an R01 grant to support the clinical
trial. A pilot clinical grant to plan a large clinical trial
(deﬁned as a trial projected to exceed $500,000 direct
costs per year) will only be accepted after prior discus-
sions and approval from NIDDK staff. Both new and
experienced investigators in relevant ﬁelds and disci-
plines are encouraged to apply for these grants.
It is anticipated that applications submitted in
response to this PAR will focus on clinical studies.
Basic laboratory research, studies of laboratory animals,
or clinical hematology studies are not appropriate for
this program announcement. Studies that do not
involve human subjects or are not human studies will
not be supported through this funding opportunity.
Applications that focus on experimental models of dis-
ease are not appropriate for this PAR, but should be
submitted to PA-05-103. 
Recent estimates of chronic kidney disease (CKD)
in the U.S. population, obtained through analysis of
the Third National Health and Nutrition Examination
Survey (NHANES III), indicate that it is a common
medical problem, affecting ≥ 10 million people in the
U.S. population. Most cases of CKD observed in the
United States occur in the setting of diabetes, hyper-
tension, glomerulonephritis, and polycystic kidney dis-
ease. The incidence of end-stage renal disease (ESRD)
has also been steadily increasing in the adult US popu-
lation. U.S. Renal Data System (USRDS) data indi-
cate that from 1992–2003 the number of patients with
ESRD has increased from 250 to 338 per million pop-
ulation. Although these rates are finally stabilizing,
these increases in ESRD rates reﬂect a marked increase
in patient morbidity and mortality related to underly-
ing kidney disease, as well as a signiﬁcant increase in
use of health care resources to provide appropriate care
for affected patients. The increasing rate of ESRD has
also markedly increased waiting time for cadaveric
transplantation such that the rate of kidney transplants
per patient year on dialysis has steadily declined over
the last decade, from 6.7 per 100 dialysis patients in
1991 to 4.7 in 2003. 
Acute kidney injury (AKI; also called acute renal
failure) in hospitalized patients is also a signiﬁcant prob-
lem in the United States. Medical management of acute
kidney injury has traditionally consisted of supportive
care, with renal replacement therapy implemented for
the most severe cases. Despite such interventions in
acute kidney injury, however, mortality rates in affected
patients remain very high (> 50% in some series).
In view of these observations suggesting a high
prevalence of CKD, and increasing ESRD and AKI in
the U.S. population, NIDDK has sponsored a number of
large, multicenter studies of specific kidney disorders.
These studies include prospective investigations in
chronic kidney disease, dialysis access, polycystic kidney
disease, focal and segmental glomerulosclerosis, and acute
kidney injury. In planning and performing these studies,
however, it has been apparent that the process for identi-
fying appropriate interventions for both single and multi-
center trials in kidney disease could be improved. This is
particularly evident in the current small number of clini-
cal studies related to kidney disease that could ultimately
be expanded to large-scale clinical trials. 
Urological diseases and disorders inﬂict a signiﬁcant
impact on the health care burden of the United States.
The NIDDK-funded Urologic Diseases in America
Project (UDA) has published data on the four of the
most prevalent nonmalignant urological diseases. The
data indicate that in 2000, benign prostatic hyperplasia
was the primary diagnosis in > 4.4 million ofﬁce visits,
424,000 emergency room visits and 121,000 hospitaliza-
tions with an annual expenditure of > $1.1 billion,
besides the increasing cost for outpatient pharmaceuticals.
The annual expenditures for urolithiasis totaled more that
$2 billion and appears to be increasing with time as the
prevalence of stone disease also increases. The health care
burden for urinary tract infections, excluding the costs of
outpatient pharmaceuticals, exceeded $2.47 billion. 
The data for the health care burden of urinary
incontinence are more difﬁcult to accurately ascertain
because a large percentage of women and men do not
report or access care for urinary incontinence.
However, the UDA reported that medical expendi-
tures and outpatient visits for urinary incontinence
more than doubled from 1992 to 1998. The data for
other nonmalignant urological diseases and disorders
such as erectile dysfunction, the chronic pelvic pain
syndromes such as chronic prostatitis and interstitial
cystitis, and the many congenital and acquired pedi-
atric urological disorders are not as rigorous but still
demonstrate large and growing health care burden.
The morbidity of many of these nonmalignant
urological disorders is compounded by other com-
mon comorbid conditions such as diabetes and obe-
sity. Advancement in accurate diagnosis, prevention,
and treatment of these diseases is hampered by many
factors including a lack of vigorously validated meth-
ods to access disease progression, by a lack of insight
into the genetics of the disorders, by well-formulated
and-tested definitions of the disease and its subcate-
gories, by a lack of rigorous epidemiologic data, and
by an imperfect understanding of the mechanism of
action of the drugs used to alleviate the symptoms of
these diseases and disorders. In addition, often the
armamentarium of available diagnostic approaches
has not been applied to these diseases. 
The goal of this PAR is to provide ﬂexibility for
initiating preliminary, short-term studies, thus allow-
ing new ideas to be investigated in a more expedi-
tious manner without stringent requirements for
preliminary data. Such support is needed to encour-
age new and experienced investigators to pursue new
approaches, underdeveloped topics, or more risky
avenues of research. If successful, these awards should
lead to signiﬁcant scientiﬁc advances in the treatment
of kidney diseases.
As the kidney and urological diseases occur in a vari-
ety of clinical settings, and are associated with a number
of comorbid conditions, applications submitted in
response to this PAR could address a number of different
aspects concerning the prevention, diagnosis, or treat-
ment of patients with kidney and urological diseases.
Relevant topics of study evaluating kidney disease in
adults or children could include, but are not limited to 1)
diagnosis, epidemiology, disease progression, prevention,
preemption, or therapy of patients with, or at risk for, the
following conditions: chronic kidney disease, including
studies of diabetic nephropathy; hypertensive nephroscle-
rosis, polycystic kidney disease, or renal allograft dysfunc-
tion; glomerular disease, either idiopathic or secondary
glomerular involvement in a systemic process; acute kid-
ney injury, including that observed following renal trans-
plantation; comorbid conditions associated with reduced
kidney function; 2) studies assessing dialysis therapy, dial-
ysis access, anemia of renal disease, nutritional, or cardio-
vascular aspects of ESRD and other comorbid conditions
associated with ESRD.
Relevant topics for study of the nonmalignant uro-
logical diseases in adults or children could include, but are
not limited to 1) diagnostic tools and instruments that can
asses the extent and physiological parameters of disease
and evaluate disease progression or response to therapy; 2)
improved diagnostic criteria for diseases and disease sub-
categories; 3) accurate epidemiologic data on diseases in
various ethnic and racial groups; 4) validated strategies to
access early detection of disease, for disease progression
and for response to therapy; 5) novel approaches to pre-
venting the onset of disease or preventing the progression
of established disease; 6) studies of the effect of the treat-
ment of comorbid disorders on the symptoms, progres-
sion, and morbidity of urological diseases.
This funding opportunity will use the NIH
Exploratory/Development Research Grant (R21) award
mechanism. Information on R21 mechanism is avail-
able at http://grants.nih.gov/grants/guide/pa-ﬁles/PA-
03-107.html. These R21 grants will not be renewable;
continuation of projects developed under this program
will be through the regular research grant (R01) pro-
gram as new applications. As an applicant, you will be
solely responsible for planning, directing, and executing
the proposed project. 
This funding opportunity uses just-in-time con-
cepts. It also uses the modular as well as the nonmodular
budget formats (see http://grants.nih.gov/grants/fund-
ing/modular/modular.htm). Speciﬁcally, if you are sub-
mitting an application with direct costs in each year of
$250,000 or less, use the modular budget format
described in the PHS 398 application instructions.
Otherwise follow the instructions for nonmodular
research grant applications. 
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. Applicants must
use the currently approved version of the PHS 398. For
further assistance contact Grants Info, 301-435-0714
(telecommunications for the hearing impaired: TTY
301-451-0088) or by e-mail: GrantsInfo@nih.gov.
Applications must be prepared using the most cur-
rent PHS 398 research grant application instructions and
forms. Applications must have a D&B Data Universal
Numbering System (DUNS) number as the universal
identiﬁer when applying for Federal grants or coopera-
tive agreements. The D&B number can be obtained by
calling 866-705-5711 or through the web site at
http://www.dnb.com/us/. The D&B number should be
entered on line 11 of the face page of the PHS 398 form. 
The application submission dates for this PA are
available at http://grants.nih.gov/grants/funding/
submissionschedule.htm. The complete version of this
PA is available at http://grants/nih.gov/grants/guide/
pa-ﬁles/PAR-06-112Fellowships, Grants, & Awards
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Contacts: Robert A. Star, Division of Kidney,
Urologic and Hematologic Diseases, National Institute
of Diabetes and Digestive and Kidney Diseases, 6707
Democracy Blvd., Room 612, Bethesda, MD 20892-
5458 USA, 301-594-7717, fax: 301-480-3510, e-mail:
rs301p@nih.gov; Catherine Meyers, Division of Kidney,
Urologic and Hematologic Diseases, National Institute
of Diabetes and Digestive and Kidney Diseases, 6707
Democracy Boulevard, Room 725, Bethesda, MD
20892-5458 USA, 301-594-7717, fax: 301-480-3510,
e-mail: cm420i@nih.gov. Reference: PAR-06-112
Autism Centers of Excellence (R01) 
Autism spectrum disorders (ASD) are complex neu-
rodevelopmental disorders with early childhood onset.
ASD prevalence may be increasing, and ASD is more
common than previously thought. These disorders,
for which there is presently no cure and only limited
treatments, generally have lifelong effects. 
The NIH currently supports a vast array of pro-
jects in autism research. Centers such as the STAART
(Studies to Advance Autism Research and Treatment)
and CPEA (Collaborative Programs of Excellence in
Autism) programs support some of these investigations.
The CPEA program, an international program begun
in 1997, now includes nine centers. These Centers
focus research on the possible causes of autism, includ-
ing genetic, immunological, and environmental factors.
The CPEA program resulted from a congressionally
mandated conference on the State of the Science in
Autism. The attendees identiﬁed gaps in the knowledge
of autism and directions for future research. Both
NICHD and NIDCD sponsor the current CPEA pro-
gram. As a result of the efforts of researchers afﬁliated
with the CPEA, data now exist on the genetics and out-
ward characteristics of the largest group of well-diag-
nosed persons with autism in the world. After the
establishment of the CPEA Centers program, Congress
enacted the Children's Health Act of 2000. This legis-
lation mandated the establishment of a new autism
research program. In response, the ﬁve Institutes of the
NIH Autism Coordinating Committee (NIH-ACC;
represented by NICHD, NIDCD, NIEHS, NIMH,
and NINDS) implemented the STAART program.
Each of the eight currently funded STAART Centers
contributes to the autism research base in the areas of
causes, diagnosis, early detection, prevention, and treat-
ment. Collaborations among the STAART centers
include a multisite psychopharmacological clinical trial.
The CPEA and the STAART programs interact exten-
sively through a shared data coordination center.
Consolidation of funding from the CPEA and
STAART programs is now needed to maximize coordi-
nation and cohesion of NIH-sponsored efforts in
autism research. The new autism centers and networks
will be called the Autism Centers of Excellence or ACE.
The focus of the ACE must be on the causes and
best treatment of autism (as listed in the autism research
matrix http://www.nimh.nih.gov/autismiacc/research-
matrix.pdf). In February 2003, Congress requested that
the Department of Health and Human Services
(DHHS) develop a set of autism research goals and
activities for the next several years (House Report 109-
10). Input into this activity included a meeting of
autism investigators with a range of scientiﬁc expertise as
well as input from community members. Preparation
for specifying this matrix involved a two-day meeting of
an expert panel of scientists; public presentation and dis-
cussion of a draft matrix at the Autism Summit
Conference in Washington DC on 20 Novembwe
2003; and adoption of the matrix by the Federal
Interagency Autism Coordinating Committee (IACC). 
Research projects should focus on ﬁnding causes
and preventive intervention for autism as well as
improved treatment. Applications should incorporate
the latest techniques and propose studies to advance
key goals related to causes and best treatment on the
autism research matrix. Examples include, but are not
limited to 1) identiﬁcation of individual characteristics
that predict response to behavioral, pharmacologic, and
other treatments; 2) identification of environmental
factors (e.g., viruses, medication, lifestyle factors, envi-
ronmental chemicals) that contribute to the develop-
ment of autism and their associated developmental
windows; 3) identification of the biologic and/or
behavioral markers to develop indices of risk for the
development of autism in infants; 4) intervention
methods for infants and toddlers developed to lower
the age for which there are efﬁcacious interventions; 5)
multisite randomized clinical trials to identify modera-
tors and effective ingredients (e.g., dose, intensity,
mode of delivery, age of onset) of early intervention
treatments; 6) multisite longitudinal study of subse-
quent pregnancies and infant siblings of children with
autism to identify risk factors, broader phenotype, and
early characterization of autism; 7) innovative and
newly developed intervention strategies to improve out-
comes in school and community settings throughout
the lifespan (e.g., academic functioning, social and
adaptive behavior, family functioning, employment),
including transitions; 8) development of efficacious
drug treatments that target core symptoms of autism;
9) characterization of the neuropathology of autism to
identify impaired brain structures and functions;
10) identification of susceptibility genes and animal
models of autism for further study of phenotypic char-
acteristics of autism.
NIH will consider centers as well as networks in
response to the ACE initiative. This funding oppor-
tunity solicits applications for ACE Networks sup-
ported by the R01 mechanism. A companion RFA
(RFA-HD-06-016) solicits applications for ACE
Centers supported by the P50 mechanism. 
This funding opportunity solicits applications for
ACE Networks. A network will consist of multiple sites
focusing on a speciﬁc topic of research for R01 support
through this funding opportunity. Each network will
submit one R01 application that includes subcontracts
to the collaborating sites. An ACE Network application
must include one or more collaborative projects that
require multiple sites for optimal design and conduct of
studies. For example, an interrelated series of clinical
trials of pharmacologic, behavioral interventions, or a
combination of these, could be an example of the focus
of such a network. Other examples include, but are not
limited to, a multisite network that could conduct one
or more neuroimaging protocols and collect data using
common standards and a multisite epidemiology study
of risk factors (e.g., genetic, environmental) for ASD.
Special populations requiring large numbers of partici-
pants for each protocol may also be studied best under
a network because of enhanced recruitment and other
beneﬁts of multisite subject accrual.
A companion RFA solicits applications for ACE
Centers (RFA-HD-06-016). Centers bring together
expertise, infrastructure, and resources focused on
major questions about autism. Centers should involve
collaborations of basic and clinical scientists optimally
suited to address the research questions posed. NIH
expects Centers to provide an environment and core
resources to bring together biomedical, behavioral,
and clinical science investigators to study autism.
Collaborations involving more than one institution are
strongly encouraged to provide optimal resources and
expertise. The centers should provide investigators with
well-characterized patients and control subjects, family
information, and other scientiﬁc resources that facilitate
research projects. Applications for centers must include
a minimum of three but no more than six research
projects. The addition of core support is optional and
will depend on speciﬁc needs. 
An ACE Center must support major multidiscipli-
nary research programs, consisting of interdependent
and interrelated subprojects. Meaningful and commit-
ted interactions among the disciplines must be evident.
Subprojects may share materials, results, data, patient
populations, or methodologies. Results of one subpro-
ject may well affect the understanding and interpreta-
tion of data from another project and thereby inﬂuence
the nature of the research performed in one or more of
the other subprojects. In addition, each subproject
must have goals and objectives that focus on the com-
mon unifying theme that interrelates the subprojects.
NIH is developing a National Database for Autism
Research (NDAR) to facilitate data sharing. NDAR
(http://ndar.nih.gov) is both a database and a set of tools
for autism researchers—a national resource for collabo-
ration in autism research and clinical practice. 
All ACE Centers and Networks will be required to
contribute data to NDAR. Data sharing is required and
NDAR will be involved to facilitate sharing activities.
NDAR will function as a data repository for all ACE
projects. Central clinical coordination and local data
management for data cleaning and entry and biostatis-
tical consulting will be the responsibility of the ACE
Center or Network. Depending on the number and
size of the multsite projects, NDAR may provide Data
Coordinating Center (DCC) functions for large ACE
multisite projects to increase efﬁciencies. 
This funding opportunity will use the Traditional
Research Project Grant (R01) award mechanism. As an
applicant, you will be solely responsible for planning,
directing, and executing the proposed project. 
This funding opportunity uses just-in-time con-
cepts. It also uses the modular as well as the nonmodular
budget formats (see http://grants.nih.gov/grants/
funding/modular/modular.htm). Speciﬁcally, if you are
submitting an application with direct costs in each year
of $250,000 or less, use the modular budget format
described in the PHS 398 application instructions.
Otherwise follow the instructions for nonmodular
research grant applications.
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. Applicants must
use the currently approved version of the PHS 398. For
further assistance contact GrantsInfo, 301-435-0714
(telecommunications for the hearing impaired: TTY
301-451-0088) or by e-mail: GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B Data
Universal Numbering System (DUNS) number as the
universal identiﬁer when applying for Federal grants or
cooperative agreements. The D&B number can be
obtained by calling 866-705-5711 or through the web
site at http://www.dnb.com/us/. The D&B number
should be entered on line 11 of the face page of the
PHS 398 form. 
The letter of intent receipt date for this RFA is
July 11, 2006, with the application receipt date
August 11, 2006. The complete version of the RFA
is available at http://grants.nih.gov/grants/guide/
rfa-ﬁles/RFA-HD-06-004.html.
Contact: Alice Kau, Mental Retardation and
Developmental Disabilities Branch, Center for
Developmental Biology and Perinatal Medicine,
National Institute of Child Health and Human
Development, 6100 Executive Boulevard, Room
4B09F, MSC 7510, Bethesda, MD 20892-7510 USA,
Rockville, MD 20852 USA (for express/courier service;
non-USPS service), 301-496-1383, fax: 301-496-3791,
e-mail: kaua@mail.nih.gov. Reference RFA-HD-06-004